The aim of this study was to estimate monetary value of a QALY among heart disease patients and to identify its determinants.A cross-sectional survey with face-to-face interview was conducted with 196 cardiovascular disease patients from two heart hospitals in Tehran, Iran, to estimate the value of QALY using disaggregated and aggregated approaches. The Euro Qol -5d (EQ-5D) questionnaire, visua...

BACKGROUND Recommendations on current clinical guidelines are informed by limited economic evidence. AIMS A formal economic evaluation of three modalities of psychotherapy for patients with cluster B personality disorders. METHOD A probabilistic decision-analytic model to assess the cost-effectiveness of out-patient, day hospital and in-patient psychotherapy over 5 years in terms of cost pe...

Main Outcome Measures: Outcomes included life expectancy, quality-adjusted life expectancy, and lifetime costs. Cost-effectiveness ratios were in dollars per qualityadjusted life year ($/QALY) gained. Results: In the general population, screening 1 time, every 2 years, and annually saved 1.6, 4.4, and 5.2 QALYs per 1000 persons screened, with incremental costeffectiveness ratios of $10 100/QALY...

Objectives In this study, we compared the cost-effectiveness comparison of active surveillance (AS) and early surgery (ES) approaches for papillary thyroid microcarcinoma (PTMC) from perspective Chinese healthcare system. Methods We performed a analysis using Markov model PTMC developed to evaluate incremental ratio AS ES. Our reference case was 40-year-old woman diagnosed with unifocal (&l...

Introduction: Alteplase is widely used as an intravenous thrombolytic drug in acute ischemic stroke (AIS). Recently however, tenecteplase, a modified form of tissue plasminogen activator, has been shown to increase early recanalization rate and proven be non-inferior with similar safety profile compared alteplase. This study aims evaluate the cost-effectiveness 0.25 mg/kg tenecteplase versus 0....

STUDY DESIGN A retrospective 1-year cost-utility analysis. OBJECTIVE To determine the cost-effectiveness of using recombinant human bone morphogenic protein (rhBMP-2) in addition to autograft for 1- and 2-level lumbar fusions. SUMMARY OF BACKGROUND DATA rhBMP-2 has been studied extensively to identify its benefits, risks, patient outcomes, and costs relative to autograft [local bone or ilia...

OBJECTIVE To assess the comparative effectiveness and cost-effectiveness (cost-utility) of a 0.05% emulsion of topical cyclosporine (Restasis; Allergan Inc, Irvine, California) for the treatment of moderate to severe dry eye syndrome that is unresponsive to conventional therapy. METHODS Data from 2 multicenter, randomized, clinical trials and Food and Drug Administration files for topical cyc...

BACKGROUND The cerebrovascular accident (CVA) or stroke is the main cause of death in Brazil and little information is available on the cost of treatment. OBJECTIVE To carry out a cost-effectiveness analysis of thrombolysis in stroke, up to three hours after symptom onset, comparing the treatment with alteplase versus the conservative treatment, under the perspective of the Brazilian Public H...